Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma

Diagnostic Molecular Pathology

Volumn 21, Issue 1, 2012, Pages 1-8

  Halait, Harkanwal ^a   Demartin, Kelli ^a   Shah, Sweta ^a   Soviero, Stephen ^a   Langland, Rachel ^a   Cheng, Suzanne ^a   Hillman, Grantland ^a   Wu, Lin ^a   Lawrence, H Jeffrey ^a  

^a Roche Molecular Diagnostics   (United States)

Author keywords

companion diagnostics; malignant melanoma; mutations

Indexed keywords

B RAF KINASE; FLUORESCENT DYE; GENOMIC DNA; MELANIN; VEMURAFENIB;

ALLELE; ARTICLE; CROSS REACTION; DIAGNOSTIC TEST; GENE MUTATION; HUMAN; HUMAN CELL; MELANOMA; METASTASIS; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FORMALDEHYDE; HUMANS; INDOLES; MELANOMA; MUTATION; PARAFFIN EMBEDDING; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS; SULFONAMIDES; TISSUE FIXATION;

EID: 84857232726     PISSN: 10529551     EISSN: 15334066     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31823b216f     Document Type: Article

References (14)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954. (Pubitemid 34716871)
2. Shinozaki M, Fujimoto A, Morton DL, et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10:1753-1757. (Pubitemid 38435567)
3. Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A (V600E)) mutation in primary melanoma. J Invest Dermatol. 2007; 127:900-905. (Pubitemid 46434654)
4. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20. (Pubitemid 36068675)
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
6. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363:809-819.
7. Yang H, Higgins B, Kolinsky K, et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 2010;70:5518-5527.
8. COSMIC database. Available at (http://www.sanger.ac.uk/perl/genetics/CGP/ cosmic); release v54 July 2011.
9. Tan YH, Liu Y, Eu KW, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology. 2008;40:295-298. (Pubitemid 351563933)
10. Fadhil W, Ibrahem S, Seth R, et al. Quick-multiplex-consensus (QMC)-PCR followed by high-resolution melting: a simple and robust method for mutation detection in formalin-fixed paraffinembedded tissue. J Clin Pathol. 2010;63:134-140.
11. Angulo B, Garcia-Garcia E, Martinez R, et al. A commercial realtime PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma. J Mol Diagn. 2011;12:292-299.
12. Eckhart L, Bach J, Ban J, et al. Melanin binds reversibly to thermostable DNA polymerase and inhibits its activity. Biochem Biophys Res Commun. 2000;271:726-730. (Pubitemid 30444696)
13. Beau-Faller M, Degeorges A, Rolland E, et al. Cross-validation study for epidermal growth factor receptor and KRAS mutation detection in 74 blinded non-small cell lung carcinoma samples: A total of 5550 exons sequenced by 15 molecular French laboratories [Evaluation of the EGFR Mutation Status for the Administration of EGFR-TKIs in Non-Small Lung Carcinoma (ERMETIC) Project-Part 1]. J Thorac Oncol. 2011;6:1006-1015.
14. Bellon E, Ligtenberg MJ, Tejpar S, et al. External quality assessment for KRAS testing Is needed: setup of a European program and report of the first joined regional quality assessment rounds. The Oncologist. 2011;16:467-478.